VIP vs Enfuvirtide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Vasoactive Intestinal Peptide, Aviptadil
A naturally occurring peptide with immunomodulatory and anti-inflammatory effects. Being studied for ARDS, pulmonary hypertension, and autoimmune conditions.
Also: Fuzeon, T-20
A peptide HIV fusion inhibitor that blocks viral entry into cells. First approved drug in the fusion inhibitor class.
Key Comparison Insights
- Enfuvirtide is FDA approved, while VIP remains in research stages.
- Both peptides belong to the Immune category, suggesting similar primary applications.
- Enfuvirtide has stronger research evidence (FDA Approved) compared to VIP (Human Trials).
Detailed Comparison
| Attribute | VIP | Enfuvirtide |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | VIP binds to VPAC1 and VPAC2 receptors, triggering anti-inflammatory cascades. It relaxes smooth muscle, vasodilates, inhibits pro-inflammatory cytokines, and promotes regulatory T-cell function. Has broad immunomodulatory effects. | Enfuvirtide is a 36-amino acid peptide that binds to HIV gp41, preventing the conformational change needed for virus-cell membrane fusion. This blocks HIV entry before the virus can infect the cell. |
| Common Dosing | 50-100 mcg intranasal daily 1-2x daily, intranasal | Limited community data available See research protocols |
| Administration | IV infusion, inhaled, or intranasal | Subcutaneous injection twice daily |
| Typical Duration | Variable by indication | Ongoing as part of HIV regimen |
| Best Time to Take | Morning or as directed | Morning or as directed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Clinical trials for COVID-19 ARDS showed promising results. Research demonstrates benefits in pulmonary arterial hypertension. Studies show potential for autoimmune conditions like rheumatoid arthritis and inflammatory bowel disease. | TORO trials showed significant viral load reduction in treatment-experienced patients. Reserved for salvage therapy due to twice-daily injection requirement and injection site reactions. |
Frequently Asked Questions: VIP vs Enfuvirtide
What is the difference between VIP and Enfuvirtide?
VIP is a immune peptide that a naturally occurring peptide with immunomodulatory and anti-inflammatory effects. being studied for ards, pulmonary hypertension, and autoimmune conditions. Enfuvirtide is a immune peptide that a peptide hiv fusion inhibitor that blocks viral entry into cells. first approved drug in the fusion inhibitor class. The main differences lie in their mechanisms of action and clinical applications.
Which is better, VIP or Enfuvirtide?
Neither is universally "better" - the choice depends on your specific goals. VIP is typically used for immune purposes, while Enfuvirtide is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can VIP and Enfuvirtide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using VIP and Enfuvirtide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of VIP and Enfuvirtide is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.